FFM
Fairmount Funds Management Portfolio holdings
AUM
$772M
This Quarter Return
+23.86%
1 Year Return
+35.05%
3 Year Return
+1,168.51%
5 Year Return
+1,432.11%
10 Year Return
–
AUM
$831M
AUM Growth
+$831M
(+17%)
Cap. Flow
+$68.4M
Cap. Flow
% of AUM
8.23%
Top 10 Holdings %
Top 10 Hldgs %
79.3%
Holding
22
New
5
Increased
4
Reduced
7
Closed
2
Top Buys
| 1 |
Apogee Therapeutics
APGE
|
$62.6M |
| 2 |
Soleno Therapeutics
SLNO
|
$33.7M |
| 3 |
Kiniksa Pharmaceuticals
KNSA
|
$30.7M |
| 4 |
Immunovant
IMVT
|
$28.8M |
| 5 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$27.1M |
Top Sells
| 1 |
Spyre Therapeutics
SYRE
|
$111M |
| 2 |
Nuvalent
NUVL
|
$19.9M |
| 3 |
Kodiak Sciences
KOD
|
$13.7M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$8.07M |
| 5 |
IMGN
Immunogen Inc
IMGN
|
$1.59M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Axsome Therapeutics
AXSM
$6.05B
| $164M | 19.69% | 2,341,238 -3,742 | -0.2% | -$262K |
|
|
2
Nuvalent
NUVL
$5.52B
| $113M | 13.56% | 2,451,819 -432,673 | -15% | -$19.9M |
|
|
IMGN
3
DELISTED
Immunogen Inc
IMGN
| $94.1M | 11.32% | 5,929,592 -100,000 | -2% | -$1.59M |
|
|
4
Apogee Therapeutics
APGE
$2.17B
| $62.6M | 7.54% | +2,941,176 | New | +$62.6M |
|
5
Merus
MRUS
$4.98B
| $44.4M | 5.34% | 1,881,345 +398,940 | +27% | +$9.41M |
|
|
6
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $43M | 5.17% | 2,474,561 +1,770,102 | +251% | +$30.7M |
|
7
argenx
ARGX
$43.6B
| $41.2M | 4.95% | 83,747 +10,221 | +14% | +$5.02M |
|
8
Cogent Biosciences
COGT
$1.69B
| $34.7M | 4.17% | 3,558,975 | – | – |
|
|
9
Soleno Therapeutics
SLNO
$3.6B
| $33.7M | 4.06% | +1,142,473 | New | +$33.7M |
|
10
Enliven Therapeutics
ELVN
$1.2B
| $29.1M | 3.5% | 2,131,369 +6,744 | +0.3% | +$92.1K |
|
|
11
Immunovant
IMVT
$2.56B
| $28.8M | 3.46% | +750,000 | New | +$28.8M |
|
|
RYZB
12
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $27.1M | 3.26% | +1,221,904 | New | +$27.1M |
|
13
Dianthus Therapeutics
DNTH
$759M
| $26.4M | 3.17% | +1,928,503 | New | +$26.4M |
|
14
Viridian Therapeutics
VRDN
$1.5B
| $21M | 2.53% | 1,369,623 | – | – |
|
15
Tyra Biosciences
TYRA
$675M
| $19.2M | 2.31% | 1,393,329 -23,669 | -2% | -$326K |
|
16
Astria Therapeutics
ATXS
$349M
| $14.2M | 1.71% | 1,901,397 | – | – |
|
17
Trevi Therapeutics
TRVI
$883M
| $11.3M | 1.35% | 5,163,287 -27,073 | -0.5% | -$59K |
|
18
Terns Pharmaceuticals
TERN
$609M
| $10.3M | 1.23% | 2,040,000 | – | – |
|
|
DBVT
19
DBV Technologies
DBVT
$264M
| $9.22M | 1.11% | 6,781,150 -283,814 | -4% | -$386K |
|
|
20
Spyre Therapeutics
SYRE
$996M
| $4.64M | 0.56% | 378,421 -9,082,119 | -96% | -$111M |
|
|
VRNA
21
Verona Pharma
VRNA
$9.16B
| – | – | -381,939 | Closed | -$8.07M |
|
|
22
Kodiak Sciences
KOD
$478M
| – | – | -1,985,245 | Closed | -$13.7M |
|